Efficacy of Electromagnetic Stimulation Therapy for Chronic Prostatitis and Chronic Pelvic Pain Syndrome
1 other identifier
interventional
50
1 country
1
Brief Summary
In 1995 the National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop reached a consensus on the definition and classification of prostatitis syndromes.The commonest and yet most poorly understood of these prostatitis syndromes is category III or chronic pelvic pain syndrome (CPPS). It has been shown that, while men with CPPS have significantly higher leukocyte counts in urine and expressed prostatic secretions compared with age matched controls, inflammation and infection do not necessarily correlate with symptom severity. The lack of a direct relationship between inflammation and symptoms is supported through studies of prostate histopathology, in which moderate or severe inflammation was identified in only 5% of men with CPPS.Conventional treatment has focused on long, empirical courses of expensive broad-spectrum antibiotics, mostly of the quinolone class, with or without the concomitant use of an α-blocker and anti-inflammatory agents. At the turn of the 19th century stimulation with electrical current and changing magnetic fields was used to treat surface conditions associated with intractable pain, such as painful malignant ulcers. The analgesic benefits of pulsed electromagnetic fields for relieving pelvic pain has been investigated in women with tissue trauma and chronic refractory pelvic pain.Despite its uncertain etiology there is some evidence that the symptom complex found in CPPS may be founded at least in part in pelvic floor muscular dysfunction and/or neurogenic hypersensitivity/inflammation. We hypothesized that the application of a electromagnetic stimulation to the perineum of the subject may result in neural excitation and pelvic floor muscle stimulation to a degree that breaks the cycle of tonic muscular spasm and neural hypersensitivity/inflammation, thereby, restoring more normal pelvic floor muscular activity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Nov 2007
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2009
CompletedFirst Submitted
Initial submission to the registry
June 16, 2009
CompletedFirst Posted
Study publicly available on registry
June 17, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2009
CompletedMay 12, 2011
May 1, 2011
1.3 years
June 16, 2009
May 10, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in NIH-CPSI total and pain score
24 weeks after treatment
Secondary Outcomes (1)
Changes in - NIH-CPSI urinary, QoL impact score - Qmax/PVR - frequency/24hrs - urgency episode/24hrs - Patient perception of treatment benefit, satisfaction, willingness to continue - Goal achievement - Patient's Perception of Symptom Improvement
24 weeks of treatment
Study Arms (1)
Electromagnetic stimulation
EXPERIMENTALElectromagnetic stimulation therapy
Interventions
Electromagnetic Stimulation Therapy for 24 weeks
Eligibility Criteria
You may qualify if:
- Age ≥ 18
- NIDDK category III chronic prostatitis/chronic pelvic pain syndrome
- Symptom duration ≥ 3 months
- The sum of 1 or 2 domain of NIH-CPSI ≥ 1 point
- The sum NIH-CPSI ≥ 15 points
You may not qualify if:
- History of prostate cancer
- History of pelvic irradiation
- History of transurethral surgery
- Urinary tract infection within 6 months to screening
- Postvoid urine volume ≥ 150ml
- Interstitial cystitis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Samsung Medical Centerlead
- M-cube technologycollaborator
Study Sites (1)
Samsung Medical Center
Seoul, 135-710, South Korea
Study Officials
- PRINCIPAL INVESTIGATOR
Kyu-Sung Lee, Ph.D
Samsung Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
June 16, 2009
First Posted
June 17, 2009
Study Start
November 1, 2007
Primary Completion
March 1, 2009
Study Completion
December 1, 2009
Last Updated
May 12, 2011
Record last verified: 2011-05